Internal Medicine, Nephrology · Hammond, LA
NPI
1891751301
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
6
Hospital affiliations
16014 Doctors Blvd
Hammond, LA, 70403
Phone (985) 340-7868
Groups this clinician bills Medicare through
Medicare paid, 2024
$424K
5,474 services
Medicare patients, 2024
688
Average age 73
Drug cost, 2024
$1.9M
6,909 prescriptions
Company payments, 2025
$1,570
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Syed T Rab was code 99232 (hospital e&m - subsequent), 3,156 times for 259 patients. In total Syed T Rab billed 5,474 services in 23 codes, and Medicare paid $424K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 3,156 | 259 | $53.13 | $168K |
| 99214 Office E&M - Established | Office | 567 | 309 | $75.07 | $43K |
| 99213 Office E&M - Established | Office | 416 | 286 | $55.79 | $23K |
| 99222 Hospital E&M - Initial | Facility | 300 | 168 | $86.97 | $26K |
| 90960 ESRD Related Services (not dialysis) | Office | 292 | 52 | $240.39 | $70K |
| 90961 ESRD Related Services (not dialysis) | Office | 165 | 52 | $200.90 | $33K |
| 99233 Hospital E&M - Subsequent | Facility | 162 | 62 | $79.38 | $13K |
| 99223 Hospital E&M - Initial | Facility | 110 | 101 | $116.21 | $13K |
| 90966 ESRD Related Services (not dialysis) | Office | 91 | 13 | $200.79 | $18K |
| 90935 Hemodialysis | Facility | 71 | 29 | $46.08 | $3,271 |
| 99204 Office E&M - New | Office | 58 | 58 | $107.03 | $6,208 |
| 99239 Hospital Discharge Management | Facility | 36 | 36 | $75.47 | $2,717 |
| 90962 ESRD Related Services (not dialysis) | Office | 16 | 11 | $135.42 | $2,167 |
By year: 2022 $544K for 6,371 services; 2023 $490K for 5,864 services; 2024 $424K for 5,474 services.
Medicare prescription drug claims, 2024
In 2024, the drug Syed T Rab prescribed most often to Medicare patients was Amlodipine Besylate, with 431 prescriptions and refills. In total Syed T Rab wrote 6,909 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 431 | 957 | 122 | $2,235 |
| Calcitriol Generic | 368 | 649 | 110 | $4,543 |
| Carvedilol Generic | 329 | 705 | 90 | $2,452 |
| Nifedipine Er Nifedipine | 317 | 585 | 89 | $4,779 |
| Allopurinol Generic | 279 | 526 | 80 | $2,320 |
| Hydralazine Hcl Generic | 270 | 548 | 91 | $5,065 |
| Furosemide Generic | 246 | 472 | 97 | $1,522 |
| Auryxia Ferric Citrate | 237 | 307 | 57 | $440K |
| Olmesartan Medoxomil Generic | 209 | 424 | 62 | $2,039 |
| Potassium Chloride Generic | 193 | 340 | 53 | $3,121 |
| Doxazosin Mesylate Generic | 185 | 327 | 47 | $1,412 |
| Cinacalcet Hcl Generic | 172 | 261 | 33 | $59K |
| Metoprolol Succinate Generic | 169 | 341 | 45 | $1,888 |
| Lisinopril Generic | 148 | 296 | 50 | $587 |
| Sevelamer Carbonate Generic | 132 | 226 | 47 | $30K |
Brand drugs: 966 claims; generic drugs: 5,923 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Syed T Rab $1,570 ($1,570 in general payments such as food, travel and fees) from 21 companies. The largest payer was Calliditas Therapeutics US Inc. with $228.
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 11 | $228 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 9 | $187 |
| Amgen Inc. AMGN | 13 | $159 |
| Fresenius USA Marketing, Inc. | 9 | $137 |
| GlaxoSmithKline, LLC. GSK | 8 | $127 |
| Vifor Pharma, Inc. | 6 | $126 |
| Shield Therapeutics Inc STX.L | 6 | $103 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $94 |
| ANI Pharmaceuticals, Inc. ANIP | 3 | $63.1 |
| Aurinia Pharma U.S., Inc. AUPH | 3 | $62.5 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.